Armistice Capital Massively Cuts Position In Spectrum Pharmaceuticals Inc. (SPPI), Pours It Into Antares Pharma Inc (ATRS)

Page 2 of 2

With a market cap of $281.7 million, Antares Pharma Inc (NASDAQ:ATRS) is a specialty pharmaceutical company that focuses on self-administered parenteral pharmaceutical products. Antares Pharma Inc (NASDAQ:ATRS) managed to narrow its net loss for the second quarter to $1.5 million, compared to $9.1 million for the same quarter of last year. Its quarterly revenue jumped to $14.4 million, versus $6.3 million last year. At the end of last month, Robert Roche Jr., a Director of Antares Pharma Inc (NASDAQ:ATRS), acquired 5,000 shares of the company at $1.77 per share for an aggregate price of $8,850. Following the acquisition, Roche Jr. owns 38,172 shares of the company. Antares Pharma Inc (NASDAQ:ATRS)’s stock performance has been poor in 2015, decreasing by 27.24% year-to-date. However, on Wednesday, the stock rose by 3.31% to $1.87. Another investor that likes Antares Pharma Inc (NASDAQ:ATRS) is James E. Flynn’s Deerfield Management, which holds 20.83 million shares of the company.

Disclosure: None

Page 2 of 2